Table 2 Molecular features of analyzed patients
Molecular features | Specification | All | LTS (n = 91) | STS-1 (n = 91) | LTS (subgroup, n = 80) | STS-2 (n = 80) |
|---|---|---|---|---|---|---|
GFAP* (%) | Positive | 73.8 | 94.4 | 61.6 | 93.5 | 64.6 |
Partially negative | 25.2 | 5.6 | 37.0 | 6.5 | 33.8 | |
Negative | 1.0 | 0 | 1.4 | 0 | 1.5 | |
MGMT* (%) | Methylated | 53.7 | 70.9 | 49.0 | 71.1 | 37.2 |
Unmethylated | 46.3 | 29.1 | 51.0 | 28.9 | 62.8 | |
IDH1R132H* (%) | Positive | 11.0 | 15.4 | 7.3 | 16.7 | 11.9 |
Negative | 89.0 | 84.6 | 92.7 | 83.3 | 88.1 | |
MIB1 | Median (range) | 20 (3–90) | 18 (5–60) | 25 (8–50) | 18 (5–60) | 25 (3–90) |
Ki67 | Median (range) | 25 (8–90) | 20 (8–60) | 30 (10–90) | 25 (10–60) | 25 (10–80) |
Ki67/MIB1 | Median (range) | 25 (3–90) | 18 (5–60) | 30 (8–90) | 20 (5–60) | 25 (3–90) |
GFAP/MGMT* (%) | GFAP+/MGMT+ | 42 | 66.0 | 28.6 | 65.9 | 25.0 |
GFAP+/MGMT− | 34 | 30.2 | 35.7 | 29.5 | 37.5 | |
GFAP−/MGMT+ | 10 | 3.8 | 16.7 | 4.5 | 12.5 | |
GFAP−/MGMT− | 13 | 0 | 19.0 | 0 | 25.0 |